MDT

85.76

-0.01%↓

A

114.93

+1.35%↑

VEEV

174.59

-0.81%↓

HQY

82.54

+0.3%↑

PHR.US

8.36

+0.97%↑

MDT

85.76

-0.01%↓

A

114.93

+1.35%↑

VEEV

174.59

-0.81%↓

HQY

82.54

+0.3%↑

PHR.US

8.36

+0.97%↑

MDT

85.76

-0.01%↓

A

114.93

+1.35%↑

VEEV

174.59

-0.81%↓

HQY

82.54

+0.3%↑

PHR.US

8.36

+0.97%↑

MDT

85.76

-0.01%↓

A

114.93

+1.35%↑

VEEV

174.59

-0.81%↓

HQY

82.54

+0.3%↑

PHR.US

8.36

+0.97%↑

MDT

85.76

-0.01%↓

A

114.93

+1.35%↑

VEEV

174.59

-0.81%↓

HQY

82.54

+0.3%↑

PHR.US

8.36

+0.97%↑

Search

KemPharm Inc

Open

0

Overview

Share price change

24h

Current

Min

Max

Key metrics

By Trading Economics

Income

13M

12M

Sales

8.1M

34M

P/E

Sector Avg

6.978

57.05

Profit margin

35.648

Employees

61

EBITDA

8.2M

9.7M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+154.4% upside

Dividends

By Dow Jones

Next Earnings

12 May 2026

Market Stats

By TradingEconomics

Market Cap

40M

553M

Previous open

0

Previous close

0

KemPharm Inc Chart

Past performance is not a reliable indicator of future results.

Related News

31 Mar 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Nike, RH, NCino

31 Mar 2026, 22:35 UTC

Earnings

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 Apr 2026, 00:00 UTC

Acquisitions, Mergers, Takeovers

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 Mar 2026, 23:50 UTC

Acquisitions, Mergers, Takeovers

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 Mar 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 Mar 2026, 23:33 UTC

Market Talk
Major News Events

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 Mar 2026, 23:21 UTC

Earnings

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 Mar 2026, 23:14 UTC

Market Talk
Earnings

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 Mar 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 Mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss Widens >000002.SZ

31 Mar 2026, 22:36 UTC

Earnings

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 Mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 Mar 2026, 22:36 UTC

Earnings

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 Mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 Mar 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 Mar 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 Mar 2026, 21:35 UTC

Earnings

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 Mar 2026, 21:35 UTC

Earnings

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 Mar 2026, 21:35 UTC

Earnings

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 Mar 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 Mar 2026, 21:33 UTC

Earnings

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 Mar 2026, 21:32 UTC

Earnings

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 Mar 2026, 21:28 UTC

Earnings

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 Mar 2026, 21:26 UTC

Earnings

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 Mar 2026, 21:25 UTC

Earnings

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 Mar 2026, 21:24 UTC

Market Talk
Earnings

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 Mar 2026, 21:22 UTC

Earnings

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 Mar 2026, 21:22 UTC

Earnings

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 Mar 2026, 21:21 UTC

Earnings

Nike's Digital Channel Still Too Promotional, CFO Says

31 Mar 2026, 21:20 UTC

Earnings

Nike CEO: Converse Remains Important to Portfolio

Peer Comparison

Price change

KemPharm Inc Forecast

Price Target

By TipRanks

154.4% upside

12 Months Forecast

Average 23.71 USD  154.4%

High 26 USD

Low 21 USD

Based on 8 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

8

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

help-icon Live chat